In Focus

  • 04 November 2020 First new arrivals of highly pathogenic avian influenza H5 in the EU

    First new arrivals of highly pathogenic avian influenza H5 in the 2020-2021 winter in Europe

    Highly pathogenic avian influenza viruses of the H5N8 and H5N1 subtypes were detected in the Netherlands in October 2020. The HA genes of the two viruses are closely related, but the other genes of the H5N1 viruses appear to originate from other virus lineages circulating in Eurasia. The earliest virus detections were on 16 October in Eurasian wigeons, a long-distance migrant, and four full virus genomes were uploaded to GISAID by late October.

    The virus genome sequences are suggestive for new virus introductions into the EU, different from the outbreaks of last winter. Previously, scientists from the Global Consortium for H5N8 and Related Influenza Viruses used GISAID data to investigate the role of migratory wild birds.

    > read more    

  • 30 October 2020 - The "new" European variant in the news

    3D structural position of Spike A222V mutation

    New hCoV-19 variant in Europe, part of natural evolution

    The newest variant of the coronavirus responsible for COVID-19 circulating in Europe features an A222V mutation in the spike glycoprotein and is designated as clade GV, part of the clade G. The mutation is not at the receptor binding site but pointing away from it and may, if anything, affect stability of the protein complex with a less pronounced effect than D614G based on its structural position and also not expected to change antibody binding much, depending on the site where the antibody binds.

    It's current strong rise within Europe and the age group bias towards young adults could simply point to a founder effect. A222V occurred about 11k times in GISAID submitted genomes (out of 167k) and apart from a handful of exceptions from travel imports, had been restricted to Europe so far.

  • CBD Study finds GISAID might provide useful lessons and insight to ABS discussion

    CBD Study finds 'GISAID might provide useful lessons and insight to ABS discussions'

    A peer-reviewed fact-finding and scoping study on digital sequence information on genetic resources in the context of the Convention on Biological Diversity and the Nagoya Protocol, highlights key advantages of GISAID’s sharing mechanism and a fair and equitable benefit-sharing resulting from access to data.

    With the core principals of timely international sharing of health data for protecting populations against lethal infectious disease outbreaks and adherence to scientific etiquette of acknowledgement of the source of data has resulted in global trust and confidence in GISAID. 

    > download the fact-finding & scoping study

  • 19 May 2017 G20 Health Ministers

    G20 Health Ministers recognize the importance of GISAID in regard to virus data sharing

    At the invitation of Germany, the first meeting of Health Ministers of the Group of Twenty leading industrialized and emerging economies (G20) took place in Berlin between 19-20 May 2017.

    Under the banner of “Together Today for a Healthy Tomorrow – Joint Commitment for Shaping Global Health”, the two-day meeting focused on combating global health hazards. In their Berlin Declaration, the G20 Health Ministers recognize the importance of the Global Initiative on Sharing All Influenza Data (GISAID).

    > read more
    > The Berlin Declaration of the G20 Health Ministers (2017)

 

 

Interactive Real-Time Mutation Tracker

Michigan State University (USA)
Explore and animate mutations over time

Interactive Real-Time Mutation Tracker

Michigan State University (USA)
Explore and animate mutations over time

hCoV-19 Data Sharing via GISAID

Public-Private Partnerships of the GISAID Initiative

The GISAID Initiative involves public-private-partnerships between the Initiative's administrative arm Freunde of GISAID e.V., a registered non-profit association, and governments of the Federal Republic of Germany, the official host of the GISAID platform, Singapore and the United States of America, with support from private and corporate philanthropy.